drugset / Trial / NCT05616208

Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence

NCT05616208 ↗

Phase 1 Active not recruiting 10 enrolled Cellf Bio LLC
NaSingle-groupOpen-labelTreatment

Summary

This is first-in-human prospective Phase I study of the immediate and long-term safety of an implanted internal anal sphincter (IAS) bioengineered from autologous cells to treat subjects with severe passive FI who have failed standard treatments.

Timeline

Start
2022-11-02
Primary completion
2027-07
Completion
2027-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bioengineered Internal Anal Sphincter Cell therapy — Other

Indications

No indication recorded.